Sujal Patel Buys 116,500 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal Patel bought 116,500 shares of the stock in a transaction on Friday, September 5th. The shares were acquired at an average cost of $0.67 per share, with a total value of $78,055.00. Following the purchase, the chief executive officer owned 10,258,221 shares of the company’s stock, valued at approximately $6,873,008.07. This represents a 1.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Nautilus Biotechnology Trading Up 5.5%

Shares of NASDAQ NAUT opened at $0.71 on Thursday. The stock has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.81. Nautilus Biotechnology, Inc. has a 12 month low of $0.62 and a 12 month high of $3.09. The company has a market cap of $89.30 million, a price-to-earnings ratio of -1.36 and a beta of 1.42.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Thursday, July 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. On average, sell-side analysts predict that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of Nautilus Biotechnology by 37.1% in the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock valued at $83,000 after buying an additional 13,363 shares during the period. Barclays PLC increased its stake in shares of Nautilus Biotechnology by 17.9% in the fourth quarter. Barclays PLC now owns 125,204 shares of the company’s stock valued at $210,000 after buying an additional 19,030 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $34,000. Presidio Capital Management LLC increased its stake in shares of Nautilus Biotechnology by 246.6% in the second quarter. Presidio Capital Management LLC now owns 34,664 shares of the company’s stock valued at $25,000 after buying an additional 24,664 shares during the period. Finally, Sentinel Trust Co. LBA increased its stake in shares of Nautilus Biotechnology by 9.8% in the first quarter. Sentinel Trust Co. LBA now owns 280,000 shares of the company’s stock valued at $241,000 after buying an additional 25,000 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.